Clinical Trial Update: Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

View source ↗

Summary

A clinical trial is investigating cutaneous phosphorylated alpha-synuclein as a biomarker to identify essential tremor patients who may progress to Parkinson's …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Tremor
• Parkinson Disease

Snippet

Sponsor: CND Life Sciences | Conditions: Essential Tremor, Movement Disorders, Essential Tremor | Status: RECRUITING